2 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
Follow Nathan Denlinger: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2024-01-29 | 2026-02-27 |
Lymphoma, Large B-Cell, Diffuse (1)
Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Biopsy (1) · CT-P10 (1) · CTL019 chimeric antigen receptor (1) · Cyclophosphamide (1) · Leukapheresis (1) · Rituximab (1) · Whole-Body Irradiation (1) · fludarabine (1) · tisagenlecleucel (1)
United States (2)